Immunovant, Inc. (IMVT) Stock
6 of the hedge funds AlphaScala tracks reported IMVT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $47.80M. Company insiders reported 0 open-market buys and 9 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own IMVT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.24M | $47.80M | NEW |
| Renaissance Technologies Jim Simons (founder) | 727K | $28.00M | +278% |
| Millennium Management Israel Englander | 329K | $12.66M | NEW |
| Citadel Ken Griffin | 160K | $6.17M | +11% |
| Marshall Wace | 142K | $5.49M | -14% |
| Greenlight Capital David Einhorn | 94K | $3.60M | n/a |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Immunovant, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 7, 26 | Stout Jay S | Chief Technology Officer | SELL | 2.2K | $71K |
| Oct 7, 26 | Stout Jay S | Chief Technology Officer | SELL | 1.6K | $51K |
| Oct 7, 26 | Gloria Melanie | Chief Operating Officer | SELL | 2.2K | $72K |
| Oct 7, 26 | Van Tuyl Christopher | Chief Legal Officer | SELL | 1.3K | $43K |
| Oct 2, 26 | Venker Eric | Chief Executive Officer | SELL | 3.5K | $120K |
| Sep 23, 26 | Van Tuyl Christopher | Chief Legal Officer | SELL | 2.8K | $103K |
| Aug 28, 26 | Pande Atul | Director | SELL | 1.5K | $65K |
| Aug 20, 26 | Gloria Melanie | Chief Operating Officer | SELL | 3.1K | $135K |
| Jul 24, 26 | Pande Atul | Director | SELL | 1.5K | $60K |
| Jul 23, 26 | Girao Tiago | Chief Financial Officer | SELL | 6.8K | $263K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →IMVT price chart
Powered by TradingViewWhat does Immunovant, Inc. do?
Immunovant Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases. The company's primary objective is to create targeted treatments that address the underlying causes of these conditions, rather than merely alleviating symptoms. Immunovant is particularly renowned for its work in exploring novel pathways and biological mechanisms that contribute to autoimmune disorders, aiming to deliver groundbreaking therapies that can significantly improve patient outcomes. The firm operates within the healthcare sector, specifically under the biotechnology industry, which is instrumental in advancing medical science and providing new therapeutic options. Immunovant's developmental pipeline includes promising drug candidates that target debilitating and often undiagnosed autoimmune disorders, reflecting its commitment to addressing unmet medical needs. As a player in the biopharmaceutical landscape, Immunovant contributes to the dynamic field of medical innovation, which is crucial to the global healthcare system. By leveraging cutting-edge research and strategic partnerships, the company is positioned at the forefront of efforts to transform patient care and enhance quality of life for individuals affected by challenging autoimmune conditions.